MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Treatment Of Advanced Parkinson’s With Levodopa–Entacapone–Carbidopa Intestinal Gel – Impact On Dyskinesia

    B. Amlani, N. Smith (Reading, United Kingdom)

    Objective: To evaluate the effect of long-term treatment with levodopa–entacapone–carbidopa intestinal gel (LECIG) infusion on daily time with dyskinesia in people with advanced Parkinson’s disease…
  • 2025 International Congress

    Opicapone for OFF Motor Fluctuations in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials

    A. Fornari Caprara, J. Pitton Rissardo (Camden, USA)

    Objective: To evaluate the efficacy of opicapone 50 mg in reducing OFF time and improving motor function in Parkinson’s disease (PD) patients with motor fluctuations.…
  • 2025 International Congress

    COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Six Months Analysis Of REONPARK Study

    L. López-Manzanares, M. Cerdán Sánchez, B. Solano Vila, J. García-Caldentey, A. Rodríguez-Sanz, J. Olivares Romero, H. Brigas, D. Martins, J. Blanco Ameijeiras, M. Rodríguez-de Miguel (Madrid, Spain)

    Objective: The REONPARK study aims to evaluate COMT inhibitors (COMTi) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s disease (PD)…
  • 2025 International Congress

    Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    A. Al Midani, A. Ahmad, O. Razouk, L. Mohamedali, M. Al Khalidi, B. Al Karam, A. Khater (Sharjah, United Arab Emirates)

    Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…
  • 2025 International Congress

    Comparative Efficacy and Safety of Opicapone in Parkinson’s Disease: An Updated Systematic Review and Meta-Analysis

    A. Abunamoos, Y. Aljazi, F. Qtaishat, A. Rababah, M. Mustafa, F. Alnajjar, M. Alghaniem (Amman, Jordan)

    Objective: To evaluate the efficacy and safety of Opicapone drug in patients with Parkinson’s disease (PD) using an updated systematic review and meta-analysis, including newly published randomized controlled trials…
  • 2025 International Congress

    Serum based estimations of CFAH, Gelsolin, CNDP1 and DKK3 levels suggest involvement of multiple pathways in pathogenesis of Parkinson’s disease.

    P. Alladi, S. Choudhury, H. Jyothi, R. Bhavani, V. Holla, A. Mahadevan, N. Kamble, P. Pal, R. YADAV. (Bengaluru, India)

    Objective: To estimate levels of complement factor H (CFAH), phosphorylated alpha-syn (p- a-syn), gelsolin, carnosine dipeptidase-1 (CNDP1) and DKK3 in serum of Parkinson’s disease (PD) patients…
  • 2025 International Congress

    Identification of Metabolomic & Proteomic Panels for Parkinson’s Disease progression Diagnosis

    A. Galal, A. Moustafa, M. Salama (Cairo, Egypt)

    Objective: Identify proteomic and metabolomic biomarkers for Parkinson’s Disease (PD) progression diagnosis using statistical and machine learning (ML) approaches, leveraging data from cerebrospinal fluid (CSF)…
  • 2025 International Congress

    Privacy and Personalisation: Predicting Parkinson’s Severity with Federated Learning

    C. Hinchliffe, H. Hiden, E. Packer, P. Brown, A. Yarnell, L. Rochester, L. Alcock, M. Peeters, S. Del Din, P. Watson (Newcastle upon Tyne, United Kingdom)

    Objective: To improve privacy and personalisation for artificial intelligence (AI), this work compared federated learning (FL) to a conventional, centralised system for predicting Movement Disorder…
  • 2025 International Congress

    Dried Plasma Spot Cards for Measurement of Neurofilament Light Chain

    B. Huxford, P. Gklinos, F. Rios, N. Vickaryous, L. Schalk, A. Noyce, R. Dobson (London, United Kingdom)

    Objective: Evaluate measurement of neurofilament light chain (NfL) in dried plasma spot cards, and to compare these to measurements using more invasive and in person…
  • 2025 International Congress

    Cognitive and Motor Wobbling in Isolated RBD: A Multicentric Study by the International RBD Study Group (IRBDSG)

    A. Stefani, S. Joza, D. Arnaldi, L. Baldelli, G. Benbir, B. Boeve, V. de Cock, L. Churchill, B. Högl, M. Hu, B. Huang, R. Kim, K. Kufer, J-Y. Lee, C. Liguori, B. Mollenhauer, L. Muntean, N. Li, B. Orso, M. Patyjewicz, R. Postuma, F. Provini, S. Lewis, C. Simonet, M. Sommerauer, A. Videnovic, Y. Wing, C. Trenkwalder (Innsbruck, Austria)

    Objective: To define and characterize clinically fluctuating transition phases from isolated RBD (iRBD) to overt alpha-synucleinopathy. Background: Patients with iRBD often develop motor and non-motor…
  • « Previous Page
  • 1
  • …
  • 133
  • 134
  • 135
  • 136
  • 137
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #25179 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley